Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech Cathflo Activase is approved

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA clears tissue plasminogen activator alteplase Sept. 4 for restoring function to occluded central venous access catheters. Genentech's Cathflo Activase will be sold in 2 mg single-use vials, while Activase, indicated for acute MI, acute ischemic stroke and acute massive pulmonary embolism, is sold in 50 and 100 mg vials (Pharmaceutical Approvals Monthly, February 2001, p. 18). The only other product approved for clearing occluded catheters is Abbott's Abbokinase (urokinase), which was pulled from the market in 1999 for GMP deficiencies. Abbott anticipates re-launching its drug in first quarter 2002
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS001593

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel